Short answer: after patent expiry, Yervoy (ipilimumab) is likely to lose market share to biosimilars and to competing cancer immunotherapies, with the size of the loss depending on region, indications, and how quickly biosimilars enter the market. It will probably still have some role, especially in approved combination regimens or niche indications, but the overall share as a stand-alone therapy will shrink.
Here’s a practical way to think about it and what to watch for:
- Key drivers of post-patent market share
- Biosimilar entry and pricing: Once core IP expires, biosimilar versions (if approved) typically lead to price erosion and increased competition. The speed and extent depend on regulatory approvals, interchangeability rules, and payer adoption.
- Competition from other checkpoint inhibitors: PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors often capture larger shares in many indications. Indications where ipilimumab is used mostly in combination with a PD-1 inhibitor may see patients switch to regimens that patients and payers view as more cost-effective or better tolerated.
- Clinical guidelines and real-world use: Adoption will hinge on whether guidelines continue to endorse ipilimumab-containing regimens (including combinations) and whether practitioners perceive a net clinical benefit over alternative therapies.
- Indication breadth and label expansions: Yervoy’s ongoing approvals (or new indications) and the ability to justify its use in specific patient subsets will influence its share.
- Payer dynamics and access: Reimbursement decisions, biosimilar pricing, and patient access programs will shape how aggressively Yervoy is used after patent expiry.
- What the trajectory might look like (qualitative)
- Early period after expiry (1–2 years): Minimal immediate price drop if biosimilars are not yet available or are limited to certain markets; Yervoy may still hold a substantial portion of the market in places where biosimilar uptake is slow or payer barriers persist.
- Medium term (3–5 years): Biosimilars gain traction in multiple regions; price competition intensifies; the overall ipilimumab share diverts to multiple suppliers. Yervoy’s absolute volume may decline, and its share within the ipilimumab class may be more fragmented.
- Longer term (5+ years): The market settles with several biosimilar products and competing immunotherapies in play. Yervoy’s standalone market share will likely be a smaller fraction of the total immunotherapy market, though it may retain use in specific combinations or rare indications.
- Regional and indication nuances
- In regions with faster biosimilar adoption and aggressive pricing, Yervoy’s share could fall more rapidly.
- In regions with slower uptake of biosimilars or where combination regimens remain favored for certain cancers, Yervoy may retain a higher, albeit smaller, share.
- If new data or trials demonstrate a clear incremental benefit in certain settings, Yervoy could preserve or reclaim some share in those niches.
- What would make the most difference?
- Timely biosimilar approvals and successful launches.
- payer acceptance and negotiated pricing with favorable access.
- Evolution of treatment guidelines favoring or discouraging ipilimumab-containing regimens.
- Emergence of new combination strategies or new competitors with better efficacy/toxicity profiles.
If you’d like, I can tailor this to a specific region (US, EU, UK, Japan, etc.) and to particular indications (melanoma, RCC, CMM, etc.), or provide a rough qualitative forecast with scenario ranges (e.g., conservative, moderate, aggressive biosimilar adoption). I can also pull timing estimates for patent expiry and any known biosimilar filings if you want an up-to-date view.